HyQvia 100 mg/ml solution for infusion for subcutaneous use
Sponsors
Takeda Development Center Americas Inc., Lillebaelt Hospital, Universitair Medisch Centrum Utrecht
Conditions
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)Multiple MyelomaPrimary Immunodeficiency DiseasesPrimary antibody deficiency:
- Unclassified antibody deficiency (unPAD)
- IgA deficiency
- Specific polysaccharide antibody deficiency (SPAD)
- IgG subclass deficiency (IgSD)
- Common variable immunodeficiency (CVID)
- Agammaglobulinemia (X-linked or otherwise)
Phase 2
Subcutaneous immunoglobulin (HyQvia) against early infections in multiple myeloma: SHIELD
Active, not recruitingCTIS2023-505053-40-00
Start: 2023-11-30Target: 100Updated: 2025-03-10
Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in Primary Immunodeficiency Diseases (PIDD)
Active, not recruitingCTIS2022-502095-23-01
Start: 2024-09-10Target: 27Updated: 2026-01-27
Phase 3
Influencing Progression of Airway Disease in Primary Antibody Deficiency
Not yet recruitingCTIS2024-513124-41-00
Target: 100Updated: 2024-07-12
A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
RecruitingCTIS2024-517450-95-00
Start: 2025-06-23Target: 46Updated: 2025-12-01